174 related articles for article (PubMed ID: 28469776)
1. Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.
Li M; Zheng C; Xu H; He W; Ruan Y; Ma J; Zheng J; Ye C; Li W
Am J Transl Res; 2017; 9(4):1708-1719. PubMed ID: 28469776
[TBL] [Abstract][Full Text] [Related]
2. AMPK-related kinase 5 (ARK5) enhances gemcitabine resistance in pancreatic carcinoma by inducing epithelial-mesenchymal transition.
Wang X; Song Z; Chen F; Yang X; Wu B; Xie S; Zheng X; Cai Y; Chen W; Zhong Z
Am J Transl Res; 2018; 10(12):4095-4106. PubMed ID: 30662653
[TBL] [Abstract][Full Text] [Related]
3. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W
Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525
[TBL] [Abstract][Full Text] [Related]
4. WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition.
Chen J; Zhang S; Zheng X; Mao J; Xie S; Chen W; Ran X
Am J Transl Res; 2020; 12(11):7377-7385. PubMed ID: 33312374
[TBL] [Abstract][Full Text] [Related]
5. ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition.
Ye Z; Chen X; Chen X
Oncol Lett; 2018 Feb; 15(2):1511-1516. PubMed ID: 29434843
[TBL] [Abstract][Full Text] [Related]
6. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
8. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
9. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
Zheng CH; Chen XM; Zhang FB; Zhao C; Tu SS
Cell Biol Int; 2018 Sep; 42(10):1386-1394. PubMed ID: 29972256
[TBL] [Abstract][Full Text] [Related]
11. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
12. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer.
Dai HY; Ma Y; Da Z; Hou XM
Pathol Res Pract; 2018 Aug; 214(8):1130-1135. PubMed ID: 29929749
[TBL] [Abstract][Full Text] [Related]
14. Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.
Wang J; Chen Y; Xiang F; Li M; Li H; Chi J; Ren K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1505-1512. PubMed ID: 28918673
[TBL] [Abstract][Full Text] [Related]
15. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
[TBL] [Abstract][Full Text] [Related]
16. Role of ARK5 in cancer and other diseases (Review).
Mo G; Zhang B; Jiang Q
Exp Ther Med; 2021 Jul; 22(1):697. PubMed ID: 33986861
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT.
Qi Y; Yang W; Liu S; Han F; Wang H; Zhao Y; Zhou Y; Zhou D
Cancer Cell Int; 2021 Jan; 21(1):74. PubMed ID: 33494783
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway.
Jian W; Bai Y; Li X; Kang J; Lei Y; Xue Y
J Cell Biochem; 2019 Apr; 120(4):5386-5395. PubMed ID: 30367510
[TBL] [Abstract][Full Text] [Related]
19. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.
Yu Z; Cheng H; Zhu H; Cao M; Lu C; Bao S; Pan Y; Li Y
Braz J Med Biol Res; 2017 Aug; 50(10):e6147. PubMed ID: 28832761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
